D. Chien

发表

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

Hillel P. Cohen, Donna Beydoun, D. Chien, 2016, Advances in Therapy.

Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor

A. Salem, K. Freise, D. Chien, 2016, Journal of clinical pharmacology.

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL‐2 Inhibitor: Results of a Single‐ and Multiple‐Dose Study

A. Salem, D. Chien, S. Agarwal, 2016, Journal of clinical pharmacology.

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Stanley B. Cohen, Zhiying Pan, D. Chien, 2020, Clinical Rheumatology.

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma

A. Salem, D. Chien, M. Gutierrez, 2017, British journal of clinical pharmacology.

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

D. Niederwieser, R. Hájek, V. Hanes, 2020, Targeted Oncology.

Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.

M. Hurwitz, M. Sznol, A. Balar, 2022, European urology.

A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis

Stanley B. Cohen, D. Chien, V. Chow, 2020, Clinical pharmacology in drug development.

A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris®) in healthy male subjects

V. Hanes, D. Chien, D. Mytych, 2020, European journal of haematology.

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

M. Hurwitz, M. Sznol, A. Balar, 2022, Journal for ImmunoTherapy of Cancer.

PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

D. Schadendorf, P. Ascierto, G. Boland, 2022, Future oncology.

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

C. Flowers, L. Swinnen, J. Cordero, 2015 .